Post-operative nausea and vomiting are common complications after surgery. The researchers from Duke University Medical Center commented on rolapitant’s rapid absorption, remarkably long half-life and low potential for drug-drug interactions.
The researchers assigned groups to rolapitant in 5-mg, 20-mg, 70-mg and 200-mg doses, as well as IV ondansetron 4 mg and placebo. The researchers found that groups assigned to rolapitant 20-mg, 70-mg and 200-mg had a higher incidence of no vomiting in comparison with placebo at 24 hours after surgery.
No differences in side effect profile were observed between rolapitant and placebo.
Read the abstract on rolapitant in Anesthesia & Analgesia.
Read more on anesthesia:
–Sen. Blumenthal Requests GAO Investigation of Drug Shortages
–Airway Scope Intubation Successful in Laterally Positioned Patients
–FDA Cannot Draw Definitive Conclusion on Anesthesia in Young Children
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.